Hsbc Holdings Plc decreased Pnm Res Inc (PNM) stake by 46.7% reported in 2019Q1 SEC filing. Hsbc Holdings Plc sold 42,373 shares as Pnm Res Inc (PNM)’s stock rose 11.03%. The Hsbc Holdings Plc holds 48,371 shares with $2.29M value, down from 90,744 last quarter. Pnm Res Inc now has $4.13B valuation. The stock increased 0.37% or $0.19 during the last trading session, reaching $51.83. About 86,670 shares traded. PNM Resources, Inc. (NYSE:PNM) has risen 23.92% since June 25, 2018 and is uptrending. It has outperformed by 19.49% the S&P500. Some Historical PNM News: 08/03/2018 – MORE OPEN-SOURCE EV CHARGING INFRASTRUCTURE NEEDED: PNM CEO; 30/05/2018 – Texas power demand breaks May daily record during heat wave -ERCOT; 19/03/2018 – PNM RESOURCES INC – EXPECTED TO AFFIRM 2018 CONSOLIDATED EARNINGS GUIDANCE OF $1.82 TO $1.92 PER SHARE; 27/04/2018 – PNM RESOURCES INC QUARTERLY ONGOING DILUTED EPS $0.21; 27/04/2018 – PNM Resources 1Q EPS 19c; 20/04/2018 – DJ PNM Resources Inc, Inst Holders, 1Q 2018 (PNM); 30/05/2018 – PNM Resources’ Texas Utility Files for General Rate Review; 07/03/2018 – PNM RESOURCES SAYS ON MARCH 6, ENTERED INTO THIRD AMENDMENT TO TERM LOAN AGREEMENT, AMENDING ITS $150 MLN TERM LOAN – SEC FILING; 09/04/2018 – PNM Resources to Announce 2018 First Quarter Earnings on April 27; 13/03/2018 – PNM RESOURCES INC – EXPECTED TO AFFIRM COMPANY’S 2018 CONSOLIDATED EARNINGS GUIDANCE OF $1.82 TO $1.92 PER DILUTED SHARE
The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) is a huge mover today! The stock increased 4.34% or $0.37 during the last trading session, reaching $8.9. About 172,612 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 11.16% since June 25, 2018 and is uptrending. It has outperformed by 6.73% the S&P500. Some Historical CCXI News: 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M; 31/03/2018 – ChemoCentryx Conference Set By H.C. Wainwright for Apr. 8-10; 09/05/2018 – CHEMOCENTRYX INC – QTRLY DILUTED NET LOSS PER COMMON SHARE $0.19; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13; 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 20/04/2018 – DJ Chemocentryx Inc, Inst Holders, 1Q 2018 (CCXI)The move comes after 8 months positive chart setup for the $516.63M company. It was reported on Jun, 25 by Barchart.com. We have $9.70 PT which if reached, will make NASDAQ:CCXI worth $46.50M more.
Investors sentiment increased to 1.44 in 2019 Q1. Its up 0.51, from 0.93 in 2018Q4. It improved, as 12 investors sold ChemoCentryx, Inc. shares while 27 reduced holdings. 22 funds opened positions while 34 raised stakes. 33.34 million shares or 22.88% more from 27.13 million shares in 2018Q4 were reported. 21,772 were reported by Los Angeles Cap Mngmt Equity Rech. Aqr Cap Management Limited Liability Company invested in 22,364 shares. California Employees Retirement Systems reported 67,452 shares or 0% of all its holdings. New York-based Amer Group Incorporated has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Comml Bank Of New York Mellon accumulated 133,619 shares. Barclays Plc has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Jacobs Levy Equity Management has 51,190 shares for 0.01% of their portfolio. State Of Wisconsin Invest Board invested in 0% or 30,100 shares. Pub Employees Retirement Of Ohio invested in 99,284 shares or 0.01% of the stock. One Trading L P holds 0% or 9,979 shares. Acadian Asset Mgmt Ltd Liability Co holds 775,123 shares. Secor Limited Partnership, a New York-based fund reported 12,798 shares. Credit Suisse Ag owns 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 13,053 shares. Northern Tru Corporation has 310,007 shares. Ameriprise Fincl accumulated 261,396 shares or 0% of the stock.
Analysts await ChemoCentryx, Inc. (NASDAQ:CCXI) to report earnings on August, 8. They expect $-0.21 earnings per share, down 50.00% or $0.07 from last year’s $-0.14 per share. After $-0.23 actual earnings per share reported by ChemoCentryx, Inc. for the previous quarter, Wall Street now forecasts -8.70% EPS growth.
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $516.63 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It currently has negative earnings. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.
Since January 7, 2019, it had 0 buys, and 5 insider sales for $1.38 million activity. On Monday, January 7 Schall Thomas J. sold $242,370 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) or 20,170 shares. KANAYA SUSAN M had sold 37,893 shares worth $457,747. On Monday, January 7 the insider Cappel Markus J. sold $158,790.
More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Seekingalpha.com which released: “InflaRx downdraft engulfs ChemoCentryx, down 28% premarket – Seeking Alpha” on June 05, 2019, also Seekingalpha.com with their article: “SCYNEXIS and ReWalk Robotics among healthcare gainers; Stellar Biotechnologies and ChemoCentryx among losers – Seeking Alpha” published on June 05, 2019, Nasdaq.com published: “Takeover of little-known Baoshang casts doubt over other small Chinese banks – Nasdaq” on May 30, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Benzinga.com and their article: “66 Biggest Movers From Yesterday – Benzinga” published on June 06, 2019 as well as Finance.Yahoo.com‘s news article titled: “Hedge Funds Have Never Been More Bullish On ChemoCentryx Inc (CCXI) – Yahoo Finance” with publication date: May 09, 2019.
Among 4 analysts covering ChemoCentryx (NASDAQ:CCXI), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ChemoCentryx had 6 analyst reports since February 11, 2019 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, March 12 by H.C. Wainwright. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) has “Buy” rating given on Thursday, February 14 by Leerink Swann. The firm has “Buy” rating by FBR Capital given on Wednesday, March 27.
Analysts await PNM Resources, Inc. (NYSE:PNM) to report earnings on July, 30. They expect $0.61 earnings per share, up 15.09% or $0.08 from last year’s $0.53 per share. PNM’s profit will be $48.58 million for 21.24 P/E if the $0.61 EPS becomes a reality. After $0.13 actual earnings per share reported by PNM Resources, Inc. for the previous quarter, Wall Street now forecasts 369.23% EPS growth.
Among 3 analysts covering PNM Resources (NYSE:PNM), 0 have Buy rating, 1 Sell and 2 Hold. Therefore 0 are positive. PNM Resources had 11 analyst reports since January 14, 2019 according to SRatingsIntel. Mizuho upgraded PNM Resources, Inc. (NYSE:PNM) rating on Friday, March 8. Mizuho has “Neutral” rating and $43.5 target. The stock of PNM Resources, Inc. (NYSE:PNM) has “Underperform” rating given on Monday, January 14 by Mizuho. The firm has “Sell” rating given on Friday, March 1 by Mizuho. As per Wednesday, March 20, the company rating was maintained by Barclays Capital. The firm earned “Hold” rating on Thursday, February 28 by Wells Fargo.
Hsbc Holdings Plc increased Manhattan Assocs Inc (NASDAQ:MANH) stake by 32,055 shares to 52,008 valued at $2.87M in 2019Q1. It also upped Albemarle Corp (NYSE:ALB) stake by 69,044 shares and now owns 80,744 shares. Home Depot Inc (NYSE:HD) was raised too.
More notable recent PNM Resources, Inc. (NYSE:PNM) news were published by: Finance.Yahoo.com which released: “The PNM Resources (NYSE:PNM) Share Price Is Up 75% And Shareholders Are Holding On – Yahoo Finance” on June 10, 2019, also Finance.Yahoo.com with their article: “Consider This Before Buying PNM Resources, Inc. (NYSE:PNM) For The 2.4% Dividend – Yahoo Finance” published on May 16, 2019, Finance.Yahoo.com published: “Is BJâ€™s Wholesale Club Holdings, Inc. (BJ) A Good Stock To Buy ? – Yahoo Finance” on June 14, 2019. More interesting news about PNM Resources, Inc. (NYSE:PNM) were released by: Prnewswire.com and their article: “PNM Resources Board Introduces Two New Directors – PRNewswire” published on January 02, 2019 as well as Seekingalpha.com‘s news article titled: “PNM Resources reaffirms 2019 earnings guidance – Seeking Alpha” with publication date: March 04, 2019.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.